Cargando…
Anti-miR-17 therapy delays tumorigenesis in MYC-driven hepatocellular carcinoma (HCC)
Hepatocellular carcinoma (HCC) remains a significant clinical challenge with few therapeutic options. Genomic amplification and/or overexpression of the MYC oncogene is a common molecular event in HCC, thus making it an attractive target for drug therapy. Unfortunately, currently there are no direct...
Autores principales: | Dhanasekaran, Renumathy, Gabay-Ryan, Meital, Baylot, Virginie, Lai, Ian, Mosley, Adriane, Huang, Xinqiang, Zabludoff, Sonya, Li, Jian, Kaimal, Vivek, Karmali, Priya, Felsher, Dean W. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5814155/ https://www.ncbi.nlm.nih.gov/pubmed/29464015 http://dx.doi.org/10.18632/oncotarget.22342 |
Ejemplares similares
-
Lipid nanoparticles that deliver IL-12 messenger RNA suppress tumorigenesis in MYC oncogene-driven hepatocellular carcinoma
por: Lai, Ian, et al.
Publicado: (2018) -
MYC ASO Impedes Tumorigenesis and Elicits Oncogene Addiction in Autochthonous Transgenic Mouse Models of HCC and RCC
por: Dhanasekaran, Renumathy, et al.
Publicado: (2020) -
MYC and Twist1 cooperate to drive metastasis by eliciting crosstalk between cancer and innate immunity
por: Dhanasekaran, Renumathy, et al.
Publicado: (2020) -
MYC functions as a switch for natural killer cell-mediated immune surveillance of lymphoid malignancies
por: Swaminathan, Srividya, et al.
Publicado: (2020) -
p19ARF is a critical mediator of both cellular senescence and an innate immune response associated with MYC inactivation in mouse model of acute leukemia
por: Yetil, Alper, et al.
Publicado: (2015)